NeuroPace (Nasdaq:NPCE) announced that the first patient received their implant in the Nautilus clinical study of its RNS system.
The company’s Nautilus study evaluates the safety and efficacy of its RNS system. It aims to treat individuals aged 12 and older with drug-resistant idiopathic generalized epilepsy (IGE). This is also known as primary generalized epilepsy.
NeuroPace designed its FDA-approved RNS system as a brain-responsive neuromodulation system. It features closed-loop technology that delivers personalized, data-driven treatment targeted to the seizure source. It does so by continuously monitoring brain activity and recognizing unique seizure patterns. Through this, the system responds in real-time with stimulation to prevent a seizure.
Co-investigators Dr. Angela Crudele and Dr. Dario Englot performed the first procedure at Vanderbilt Health in Nashville, Tennessee.
“Today, we hav…